glp 1 and liver GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis Revolutionizing MASLD treatment with GLP-1

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

Prebiotic supports normal digestive health and normal Akkermansia muciniphila levels

Lisa S

Divergence across payer type matters: Commercial patients adopt GLP1s earlier and often remain on monotherapy, while Medicare patients face stricter controls and higher comorbidity burdens

PF-07976016 - oral GIPR antagonist Phase 2

Amgen is taking their own approach to weight loss with their investigational obesity drug #MariTide